Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin? | Zendy

Vincent Fleury | Zendy

Open Access

Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?

Author(s) -

Vincent Fleury

Publication year - 2020

Publication title -

american journal of epidemiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.33

H-Index - 256

eISSN - 1476-6256

pISSN - 0002-9262

DOI - 10.1093/aje/kwaa155

Subject(s) - hydroxychloroquine , azithromycin , medicine , covid-19 , case fatality rate , virology , epidemiology , microbiology and biotechnology , biology , antibiotics , outbreak , disease , infectious disease (medical specialty)

In this issue of the Journal, Dr. Risch (Am J Epidemiol. 2020;189(11):1218–1226) posits that the use of a combination of hydroxychloroquine and azithromycin as an outpatient treatment for high-risk patients with coronavirus 19 should be increased as a way to help curtail the ongoing pandemic. However, a calculation error occurred in the original article, and new data about the studies cited have come to light. Peculiarities in the methods of data collection and reporting in those original sources must be considered when evaluating the evidence for or against hydroxychloroquine and azithromycin bitherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research